POSB56 Cost-Effectiveness of Satralizumab Compared to Eculizumab for the Treatment Neuromyelitis Optica Spectrum Disorders (NMOSD) in Adult and Adolescent Patients Who Are Anti-Aquaporin 4 (AQP4) Seropositive in Canada
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.329
https://www.valueinhealthjournal.com/article/S1098-3015(21)02124-0/fulltext
Title :
POSB56 Cost-Effectiveness of Satralizumab Compared to Eculizumab for the Treatment Neuromyelitis Optica Spectrum Disorders (NMOSD) in Adult and Adolescent Patients Who Are Anti-Aquaporin 4 (AQP4) Seropositive in Canada
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02124-0&doi=10.1016/j.jval.2021.11.329
First page :
Section Title :
Open access? :
No
Section Order :
11107